We are live on
!
Find out more
Iovance Biotherapeutics
IOVA
IOVA
219 hedge funds and large institutions have $1.44B invested in Iovance Biotherapeutics in 2023 Q2 according to their latest regulatory filings, with 31 funds opening new positions, 91 increasing their positions, 65 reducing their positions, and 39 closing their positions.
New
Increased
Maintained
Reduced
Closed
85% more call options, than puts
Call options by funds: $10.9M | Put options by funds: $5.88M
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
40% more repeat investments, than reductions
Existing positions increased: 91 | Existing positions reduced: 65
14% more capital invested
Capital invested by funds: $1.25B → $1.44B (+$181M)
0.67% less ownership
Funds ownership: 91.54% → 90.88% (-0.67%)
4% less funds holding
Funds holding: 228 → 219 (-9)
21% less first-time investments, than exits
New positions opened: 31 | Existing positions closed: 39
Holders
219
Holders Change
-9
Holders Change %
-3.95%
% of All Funds
3.44%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.05%
New
31
Increased
91
Reduced
65
Closed
39
Calls
$10.9M
Puts
$5.88M
Net Calls
+$5M
Net Calls Change
+$4.32M
Top Buyers
Top Sellers
| 1 |
Morgan Stanley
New York
|
-$30M |
| 2 |
Franklin Resources
San Mateo,
California
|
-$19.2M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$15.3M |
| 4 |
DM
Deerfield Management
New York
|
-$11.2M |
| 5 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
-$11M |
